A large phase III multi-centre randomised trial to determine the impact of timing of surgery and chemotherapy in newly diagnosed patients with advanced epithelial ovarian, primary peritoneal or fallopian tube cancer
Timing drugs and surgery for best treatment of ovarian cancer
What is this study about?
Of all the gynaecological cancers, ovarian cancer causes the most deaths. A standard treatment for ovarian cancer is an operation followed by chemotherapy. In many cases, however, the operation does not remove the whole tumour. We want to know whether giving women chemotherapy before they have an operation will be more effective, as the tumour will have shrunk. The aim of this trial is to see if survival and quality of life are improved if women have their operation in the middle of the chemotherapy course rather than at the start. This trial will enable doctors to learn more about the best way to treat women with ovarian cancer in the future.
Type of study
Who is funding the study?
The charity Cancer Research UK. The Medical Research Council (MRC) and the Royal College of Obstetricians and Gynaecologists (RCOG) funded the feasibility trial.
When is it taking place?
This trial closed to recruitment in August 2010.
Where is it taking place?
Hospitals throughout the UK.
Who is included?
Newly diagnosed patients with advanced ovarian, primary peritoneal, or fallopian tube cancer.